Company Overview

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of significant unmet medical need. Headquartered in Foster City, California, and incorporated in 1987, Gilead operates globally, with a focus on advancing therapies to prevent and treat life-threatening diseases. The company's core therapeutic areas include human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer, and inflammatory diseases. Gilead Sciences is a major player in the biopharmaceutical industry, operating in more than 35 countries worldwide.

Financial Performance and Market Position

Gilead Sciences has demonstrated significant financial growth, with its market capitalization expanding substantially. The company has shown strong performance metrics, particularly in its key therapeutic areas, and maintains a healthy cash position.

Key Financial Highlights (as of December 31, 2024, and Q2 2025):

- Market Capitalization: $141.95 Billion (as of December 2024)

- Q4 2024 Product Sales: Increased 7% year-over-year to $7.5 billion.

- Excluding Veklury, product sales increased 13% to $7.2 billion, driven by strong performance in HIV, Oncology, and Liver Disease segments.

- Cash Reserves: As of December 31, 2024, Gilead held $10.0 billion in cash, cash equivalents, and marketable debt securities.

- Operating Cash Flow (Q4 2024): Generated $3.0 billion.

- Q2 2025 Revenue: Increased 2% year-over-year to $7.1 billion, driven by higher sales in HIV, Livdelzi®, and Trodelvy®, partially offset by lower chronic hepatitis C virus (HCV) and Veklury® sales.

Core Therapeutic Areas and Product Portfolio

Gilead's scientific innovation spans several critical disease areas, with a strong focus on developing transformative therapies.

HIV/AIDS Portfolio

Gilead has a long-standing leadership in HIV treatment and prevention. For over 35 years, the company has been at the forefront of developing innovative HIV medications, including the first single-tablet regimen, the first PrEP medication, and the first twice-yearly long-acting injectable treatment.

- Leading HIV Medications: The company offers a comprehensive range of HIV treatments, including Biktarvy®, Genvoya®, Descovy®, Odefsey®, Truvada®, Complera®/Eviplera®, Stribild®, Sunlenca®, and Atripla®.

- Biktarvy® Performance: Sales increased by 21% to $3.8 billion in Q4 2024 and by 9% to $3.5 billion in Q2 2025 compared to the respective prior-year periods.

Breakthrough HIV Prevention Innovation

Gilead has introduced revolutionary prevention options, such as Yeztugo® (lenacapavir), an injectable HIV-1 capsid inhibitor approved as pre-exposure prophylaxis (PrEP). This is the first and only twice-yearly option for PrEP in the U.S., making it a significant advancement in HIV prevention. Lenacapavir was recognized by the journal Science as its 2024 "Breakthrough of the Year."

Hepatitis and Liver Disease

Gilead provides crucial treatments for viral hepatitis, including epcoritamab® (seladelpar) for primary biliary cholangitis (PBC) and therapies for chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV).

- Liver Disease Portfolio: Sales increased by 4% in Q4 2024, largely due to the launch of Livdelzi® and increased demand for chronic HBV and HDV treatments.

- Key Hepatitis Medications: Includes Epclusa®, Harvoni®, Vemlidy®, and Viread®.

Oncology Portfolio

The company is expanding its oncology presence through innovative therapies, including CAR-T cell therapies and treatments for various cancers.

- Oncology Products: Includes Yescarta®, Tecartus®, and Trodelvy®.

- Cell Therapy Sales: Increased by 5% in Q4 2024. Yescarta® sales grew by 6% to $390 million in Q4 2024.

COVID-19 Treatment

Gilead offers Veklury® (remdesivir), an intravenous treatment for COVID-19.

- Veklury® Sales: Sales decreased by 53% in Q4 2024 compared to the previous year, reflecting lower hospitalization rates for COVID-19.

Innovation Pipeline

Gilead Sciences maintains a robust and diverse pipeline across its key therapeutic areas: Virology, Oncology, and Inflammation. The company is on track to achieve its ambition of delivering over 10 transformative therapies by 2030, driven by pioneering science and strategic partnerships. Numerous clinical trials and research programs are underway, focusing on advanced treatment options with varied dosing and administration methods.

Strategic Partnerships

Gilead actively collaborates with leading companies and organizations to accelerate drug discovery and development. These strategic partnerships enhance its pipeline and R&D capabilities.

- Key Collaborations Include: Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; Assembly Biosciences, Inc.; Merus N.V.; Terray Therapeutics, Inc.; and LEO Pharma.

Gilead Sciences presents a compelling investment profile, underpinned by its strong portfolio in vital therapeutic areas like HIV and hepatitis, a promising innovation pipeline, and strategic partnerships. The company's ability to generate stellar profit margins, combined with its ongoing commitment to developing transformative therapies, positions it for sustained growth and leadership in the biopharmaceutical sector.